SHANGHAI, Aug. 15, 2019 /PRNewswire/ — 111, Inc. (“111” or the “Company”) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results for the second quarter ended June 30, 2019 and US$10 million share repurchase program.
Second Quarter 2019 Highlights
Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, “We had another strong quarter. Net revenues grew by 109.2% year-over-year to RMB838.2 million, which has been our fastest growth rate since our IPO and exceeded the high end of our guidance for the third consecutive quarter. The rapid growth during the quarter was primarily driven by the continuous progress we have made in our B2B segment, where revenues grew by 253.4% year-over-year. The number of pharmacies we served increased to more than 190,000, from more than 170,000 as of March 31, 2019. Comparing to first quarter this year, our revenue of B2B business increased by 41.4% where revenue from existing stores of pharmacies increased by 24.9% and revenue from new stores contributed the growth of 16.5%.
In addition, gross profit grew 72% year-over-year to RMB42.1 million, an all-time high. Net losses continued to trend downward, demonstrating the scaling effect of our business and our effectiveness at executing our growth strategy while closely controlling costs.
As of June 30, 2019, we were directly sourcing from 124 pharmaceutical companies. We have also signed a strategic partnership agreement with MSH China, a leading premium healthcare insurance service provider, to jointly explore business opportunities in online consultation and diagnosis, chronic disease management, drug refill service and PBM model. Our customer satisfaction rate for the second quarter 2019 has increased to 99.2% from 98.9% for the first quarter 2019.
With a network of more than 190,000 pharmacies across the country and our B2C online capabilities, we believe that we have laid a solid foundation for us to build an integrated online and offline healthcare platform in China through our T2B2C[2] business model. By enabling pharmacies, pharmaceutical companies, insurance companies and doctors, we are creating value in this healthcare ecosystem on the basis of transparency and efficiency. While expanding our unique capabilities including smart supply chain, cloud solutions big data and medical expertise, we have confidence to continue our strong revenue growth and further reduce our operating expenditure in the third quarter and years ahead.”
|
[1] Operating expense consists of fulfillment expenses, selling and marketing expenses, general and administrative expenses, technology expenses and other operating expenses (net). |
|
[2] T2B2C business model refers to the business model whereby technology companies (T-side) enable businesses to better serve consumers (C-side). |
Second Quarter 2019 Financial Results
Net revenues were RMB838.2 million (US$122.1 million), representing an increase of 109.2% from RMB400.7 million in the same quarter of last year. The increase was mainly due to the significant increase in product revenues from B2B segment, which increased by 253.4% to RMB649.9 million (US$94.7 million) from RMB183.9 million in the same quarter of last year.
Operating costs and expenses were RMB939.0 million (US$136.8 million), representing an increase of 89.0% from RMB496.8 million in the same quarter of last year.
Loss from operations was RMB100.8 million (US$14.7 million), compared to RMB96.1 million in the same quarter of last year. Loss from operations accounted for 12.0% of net revenue this quarter as compared to 24.0% in the same quarter of last year.
Non-GAAP Loss from operations[3] was RMB85.3 million (US$12.4 million), compared to RMB84.5 million in the same quarter of last year. Non-GAAP loss from operations accounted for 10.2% of net revenue this quarter as compared to 21.1% in the same quarter of last year.
|
[3] Non-GAAP loss from operations represents loss from operations excluding share-based compensation. |
Net loss attributable to ordinary shareholders was RMB100.2 million (US$14.6 million), compared to RMB86.4 million in the same quarter of last year. Net loss attributable to ordinary shareholders accounted for 12.0% of net revenue this quarter as compared to 21.6% in the same quarter of last year.
Non-GAAP net loss attributable to ordinary shareholders[4] was RMB84.7 million (US$12.3 million), compared to RMB74.8 million in the same quarter of last year. Non-GAAP net loss attributable to ordinary shareholders accounted for 10.1% of net revenue this quarter as compared to 18.7% in the same quarter of last year.
Loss per ADS was RMB1.22 (US$0.18), compared to RMB2.40 for the same period of last year.
Non-GAAP Loss per ADS[5] was RMB1.03 (US$0.15), compared to RMB2.08 for the same period of last year.
As of June 30, 2019, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB987.2 million (US$143.8 million), compared to RMB1,106.5 million as of December 31, 2018.
Business Outlook
For the third quarter of 2019, the Company expects total net revenues to be between RMB1 billion and RMB1.05 billion, representing year-over-year growth of approximately 101% to 111%.
The above outlook is based on the current market conditions and reflects the Company’s current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.
Share Repurchase Program
The Company’s board of directors has authorized a share repurchase program under which the Company may repurchase its own class A ordinary shares in the form of American depository shares (“ADSs”) with an aggregate value of up to US$10 million within the next twelve months. The Company expects to fund the repurchases from its existing cash balance. The share repurchase program may be limited or terminated at any time without prior notice. Under the share repurchase program, the Company may repurchase its ADSs through open market transactions at prevailing market prices and/or in privately negotiated transactions, depending on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company’s working capital requirements, general business conditions and other factors, as well as subject to applicable rules of Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
|
[4] Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation and impairment loss of long-term investment. |
|
[5] Non-GAAP loss per ADS represents loss per ADS excluding share-based compensation and impairment loss of long-term investment per ADS. |
Conference Call
111’s management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 15, 2019 (7:30 PM Beijing Time on August 15, 2019).
Dial-in details for the earnings conference call are as follows:
|
United States: |
+ 1-845-507-1610 |
|
Hong Kong: |
+852-3051-2792 or 300-820-34 |
|
China: |
4001-203-170 or 8008-700-210 |
|
International: |
+61-283-733-610 |
|
Passcode: |
9888524 |
Please dial in 15 minutes before the call is scheduled to begin and provide the passcode to join the call.
A telephone replay of the call will be available after the conclusion of the conference call until 9:59 AM ET on August 23, 2019:
|
United States: |
+1-855-452-5696 |
|
International: |
+61-2-8199-0299 |
|
Passcode: |
9888524 |
A live and archived webcast of the conference call will be available on the Investor Relations section of 111’s website at http://ir.111.com.cn/.
Use of Non-GAAP Financial Measures
In evaluating the business, the Company considers and uses non-GAAP loss from operations, non-GAAP net loss attributable to ordinary shareholders and non-GAAP loss per ADS, non-GAAP measures, as supplemental measures to review and assess its operating performance. The Company defines non-GAAP loss from operations as loss from operations excluding share-based compensation. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation and impairment loss of long-term investment. The Company defines non-GAAP loss per ADS as loss per ADS excluding share-based compensation and impairment loss of long-term investment per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.
The Company believes that non-GAAP loss from operations, non-GAAP net loss attributable to ordinary shareholders and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in loss from operations and net loss. Share-based compensation is a non-cash expense that varies from period to period. Impairment loss of long-term investment is a non-cash expense that occurred in this period. As a result, management excludes these two items from its internal operating forecasts and models. Management believes that this adjustment for share-based compensation provides investors with a basis to measure the company’s core performance, including compared with the performance of other companies, without the period-to-period variability created by share-based compensation. The Company believes that non-GAAP loss from operations, non-GAAP net loss attributable to ordinary shareholders and non-GAAP loss per ADS provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making.
The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP loss from operations, non-GAAP net loss attributable to ordinary shareholders or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company’s operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.
The Company compensates for these limitations by reconciling the non-GAAP financial measures to the nearest U.S. GAAP measures, all of which should be considered when evaluating the Company’s performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.
Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release.
Exchange Rate Information Statement
This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.865 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of June 28, 2019.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111’s strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company’s ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company’s ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
About 111, Inc.
111, Inc. (NASDAQ: YI) (“111” or the “Company”) is a leading integrated online and offline healthcare platform in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and medical services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online medical services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy, 111 also enables offline pharmacies to better serve their customers. The Company’s online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company’s New Retail platform, by integrating the front and back ends of the pharmaceutical supply chain, has formed a smart supply chain, which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.
For more information on 111, please visit ir.111.com.cn
For more information, please contact:
111, Inc.
Ms. Monica Mu
IR Director
ir@111.com.cn
Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com
In the United States
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@ChristensenIR.com
|
111, Inc. |
|||||||
|
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
|
(In thousands, except for share and per share data) |
|||||||
|
As of |
|||||||
|
December 31, |
June 30, 2019 |
||||||
|
RMB |
RMB |
US$ |
|||||
|
ASSETS |
|||||||
|
Current Assets: |
|||||||
|
Cash and cash equivalents |
853,740 |
623,552 |
90,831 |
||||
|
Restricted Cash |
– |
54,669 |
7,963 |
||||
|
Short-term investments |
252,805 |
309,022 |
45,014 |
||||
|
Accounts receivable, net of allowance of doubtful |
28,569 |
36,450 |
5,310 |
||||
|
Inventories |
210,836 |
420,917 |
61,313 |
||||
|
Prepayments and other current assets |
161,147 |
190,627 |
27,768 |
||||
|
Note Receivable |
– |
10,698 |
1,558 |
||||
|
Total current assets |
1,507,097 |
1,645,935 |
239,757 |
||||
|
Property and equipment |
20,302 |
22,412 |
3,265 |
||||
|
Intangible assets |
4,503 |
4,834 |
704 |
||||
|
Long-term investments |
11,140 |
140 |
20 |
||||
|
Other Non-Current Assets |
3,376 |
3,322 |
485 |
||||
|
Operating lease right-of-use Assets(1) |
– |
62,459 |
9,099 |
||||
|
Total Assets |
1,546,418 |
1,739,102 |
253,330 |
||||
|
LIABILITIES AND EQUITY |
|||||||
|
Current liabilities including amounts of the |
|||||||
|
Short-term borrowings |
– |
37,253 |
5,427 |
||||
|
Accounts payable |
212,258 |
470,954 |
68,602 |
||||
|
Note Payable |
– |
16,582 |
2,415 |
||||
|
Accrued expense and other current liabilities(1) |
102,261 |
131,140 |
19,102 |
||||
|
Total Current liability |
314,519 |
655,929 |
95,546 |
||||
|
Operating Lease Liabilities(1) |
– |
39,911 |
5,814 |
||||
|
Other Non-Current Liabilities |
8,135 |
7,035 |
1,025 |
||||
|
Total Liabilities |
322,654 |
702,875 |
102,385 |
||||
|
On January 1, 2019, the company adopted ACS 842, the new lease standard, using the optional |
|
111, Inc. |
|||||||
|
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
|
(In thousands, except for share and per share data) |
|||||||
|
As of |
|||||||
|
December 31, 2018 |
June 30, 2019 |
||||||
|
RMB |
RMB |
US$ |
|||||
|
Shareholders’ Equity |
|||||||
|
Ordinary shares Class A ($0.00005 par value per share; |
29 |
29 |
4 |
||||
|
Ordinary shares Class B ($0.00005 par value per share; |
25 |
25 |
4 |
||||
|
Additional paid in capital |
2,540,878 |
2,572,718 |
374,759 |
||||
|
Accumulated deficit |
(1,383,729) |
(1,602,445) |
(233,422) |
||||
|
Accumulated other Comprehensive Income |
67,073 |
67,295 |
9,803 |
||||
|
Total shareholders’ equity |
1,224,276 |
1,037,622 |
151,148 |
||||
|
Non-controlling interest |
(512) |
(1,395) |
(203) |
||||
|
Total equity |
1,223,764 |
1,036,227 |
150,945 |
||||
|
Total liabilities and equity |
1,546,418 |
1,739,102 |
253,330 |
||||
|
111, Inc. |
|||||||||||||||||
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS |
|||||||||||||||||
|
(In thousands, except for share and per share data) |
|||||||||||||||||
|
For the three months ended June 30, |
For the six months ended June 30, |
||||||||||||||||
|
2018 |
2019 |
2018 |
2019 |
||||||||||||||
|
RMB |
RMB |
US$ |
RMB |
RMB |
US$ |
||||||||||||
|
Net Revenues |
400,740 |
838,161 |
122,092 |
730,945 |
1,493,762 |
217,591 |
|||||||||||
|
Operating Costs and expenses: |
|||||||||||||||||
|
Cost of product sold |
(376,270) |
(796,066) |
(115,960) |
(665,349) |
(1,418,400) |
(206,613) |
|||||||||||
|
Fulfillment expenses |
(16,865) |
(27,421) |
(3,994) |
(31,184) |
(48,674) |
(7,090) |
|||||||||||
|
Selling and marketing expenses |
(62,478) |
(75,038) |
(10,931) |
(104,474) |
(150,499) |
(21,923) |
|||||||||||
|
General and administrative expenses |
(24,030) |
(28,510) |
(4,153) |
(38,254) |
(56,044) |
(8,164) |
|||||||||||
|
Technology expenses |
(17,466) |
(12,299) |
(1,792) |
(30,648) |
(27,329) |
(3,981) |
|||||||||||
|
Other operating income (expenses) |
281 |
334 |
49 |
702 |
(162) |
(23) |
|||||||||||
|
Total Operating costs and expenses |
(496,828) |
(939,000) |
(136,781) |
(869,207) |
(1,701,108) |
(247,794) |
|||||||||||
|
Loss from operations |
(96,088) |
(100,839) |
(14,689) |
(138,262) |
(207,346) |
(30,203) |
|||||||||||
|
Interest income |
150 |
1,419 |
207 |
372 |
3,360 |
489 |
|||||||||||
|
Interest expense |
(4) |
(70) |
(10) |
– |
(349) |
(51) |
|||||||||||
|
Foreign exchange gain (loss) |
3,540 |
(3,165) |
(461) |
1,335 |
(6,010) |
(874) |
|||||||||||
|
impairment loss of long-term investment |
– |
– |
– |
– |
(11,000) |
(1,602) |
|||||||||||
|
Other Income, net |
5,393 |
1,959 |
285 |
7,103 |
1,746 |
254 |
|||||||||||
|
Loss before income taxes |
(87,009) |
(100,696) |
(14,668) |
(129,452) |
(219,599) |
(31,987) |
|||||||||||
|
Income tax expense |
– |
– |
– |
– |
– |
– |
|||||||||||
|
Net Loss |
(87,009) |
(100,696) |
(14,668) |
(129,452) |
(219,599) |
(31,987) |
|||||||||||
|
Net Loss attributable to non-controlling interest |
637 |
470 |
69 |
1,127 |
883 |
129 |
|||||||||||
|
Net Loss attributable to ordinary shareholders |
(86,372) |
(100,226) |
(14,599) |
(128,325) |
(218,716) |
(31,858) |
|||||||||||
|
Other comprehensive loss |
|||||||||||||||||
|
Unrealized gains of available -for-sale securities, |
4,962 |
2,465 |
359 |
5,147 |
4,220 |
615 |
|||||||||||
|
Realized gain of available-for-sale debt |
(6,673) |
(511) |
(74) |
(7,103) |
(598) |
(87) |
|||||||||||
|
Foreign currency translation adjustments |
7,208 |
19,173 |
2,793 |
2,216 |
(3,400) |
(495) |
|||||||||||
|
Comprehensive loss |
(80,875) |
(79,099) |
(11,521) |
(128,065) |
(218,494) |
(31,825) |
|||||||||||
|
Loss per share: |
|||||||||||||||||
|
Basic and diluted |
(1.20) |
(0.61) |
(0.09) |
(1.78) |
(1.34) |
(0.19) |
|||||||||||
|
Loss per ADS: |
|||||||||||||||||
|
Basic and diluted |
(2.40) |
(1.22) |
(0.18) |
(3.56) |
(2.68) |
(0.38) |
|||||||||||
|
Weighted average number of shares used in computation of loss per share |
|||||||||||||||||
|
Basic and diluted |
72,000,000 |
163,750,044 |
163,750,044 |
72,000,000 |
163,435,631 |
163,435,631 |
|||||||||||
|
111, Inc. |
||||||||||||||||
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||||||||||
|
(In thousands) |
||||||||||||||||
|
For the three months ended June 30, |
For the six months ended June 30, |
|||||||||||||||
|
2018 |
2019 |
2018 |
2019 |
|||||||||||||
|
RMB |
RMB |
US$ |
RMB |
RMB |
US$ |
|||||||||||
|
Net cash used in operating |
(28,871) |
(93,495) |
(13,619) |
(49,181) |
(152,815) |
(22,260) |
||||||||||
|
Net cash used in investing |
137,257 |
(52,570) |
(7,658) |
90,222 |
(58,999) |
(8,594) |
||||||||||
|
Net cash provided by |
277,819 |
21,491 |
3,131 |
277,819 |
42,290 |
6,160 |
||||||||||
|
Effect of exchange rate |
4,631 |
11,342 |
1,652 |
1,219 |
(5,995) |
(873) |
||||||||||
|
Net increase in cash and cash |
390,836 |
(113,232) |
(16,494) |
320,079 |
(175,519) |
(25,567) |
||||||||||
|
Cash and cash equivalents, |
96,903 |
791,453 |
115,288 |
167,660 |
853,740 |
124,361 |
||||||||||
|
Cash and cash equivalents, |
487,739 |
678,221 |
98,794 |
487,739 |
678,221 |
98,794 |
||||||||||
|
111, Inc |
||||||||||||||||
|
Unaudited Reconciliation of GAAP and Non-GAAP Results |
||||||||||||||||
|
(In thousands, except for share and per share data) |
||||||||||||||||
|
For the three months ended June 30, |
For the six months ended June 30, |
|||||||||||||||
|
2018 |
2019 |
2018 |
2019 |
|||||||||||||
|
RMB |
RMB |
US$ |
RMB |
RMB |
US$ |
|||||||||||
|
Loss from operations |
(96,088) |
(100,839) |
(14,689) |
(138,262) |
(207,346) |
(30,203) |
||||||||||
|
Add: Share-based |
11,619 |
15,576 |
2,269 |
20,286 |
26,803 |
3,904 |
||||||||||
|
Non-GAAP loss from |
(84,469) |
(85,263) |
(12,420) |
(117,976) |
(180,543) |
(26,299) |
||||||||||
|
Net Loss attributable to ordinary |
(86,370) |
(100,226) |
(14,599) |
(128,326) |
(218,716) |
(31,858) |
||||||||||
|
Add: Share-based |
11,619 |
15,576 |
2,269 |
20,286 |
26,803 |
3,904 |
||||||||||
|
Impairment loss of long-term |
– |
– |
– |
– |
11,000 |
1,602 |
||||||||||
|
Non-GAAP net Loss |
(74,751) |
(84,650) |
(12,330) |
(108,040) |
(180,913) |
(26,352) |
||||||||||
|
Loss per ADS: |
||||||||||||||||
|
Basic and diluted |
(2.40) |
(1.22) |
(0.18) |
(3.56) |
(2.68) |
(0.38) |
||||||||||
|
Add: Share-based c |
0.32 |
0.19 |
0.03 |
0.56 |
0.47 |
0.06 |
||||||||||
|
Non-GAAP Loss per ADS |
(2.08) |
(1.03) |
(0.15) |
(3.00) |
(2.21) |
(0.32) |
||||||||||
View original content:http://www.prnewswire.com/news-releases/111-inc-announces-second-quarter-2019-unaudited-financial-results-and-us10-million-share-repurchase-program-300902339.html
SOURCE 111, Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…
The new app allows users to browse services, book IV therapy, manage appointments, purchase packages,…
PHILADELPHIA, Nov. 22, 2024 /PRNewswire/ -- Independence Blue Cross (IBX) is implementing the Epic Payer Platform…
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- Report with market evolution powered by AI -…
To help improve clinician workflow and visualization during endoscopic bronchoscopy procedures, the company has added…